Smith & Nephew (LON:SN – Get Free Report) had its price objective cut by analysts at JPMorgan Chase & Co. from GBX 1,438 to GBX 1,290 in a research report issued on Thursday,London Stock Exchange reports. The firm currently has a “neutral” rating on the stock. JPMorgan Chase & Co.‘s price target indicates a potential upside of 14.97% from the stock’s current price.
A number of other research firms have also weighed in on SN. Jefferies Financial Group reiterated a “buy” rating and set a GBX 1,500 target price on shares of Smith & Nephew in a report on Wednesday. Deutsche Bank Aktiengesellschaft restated a “hold” rating and set a GBX 1,400 price target on shares of Smith & Nephew in a report on Thursday, July 30th. Shore Capital Group reaffirmed a “buy” rating and set a GBX 1,000 price target on shares of Smith & Nephew in a research report on Tuesday, July 21st. Citigroup cut Smith & Nephew to a “buy” rating in a report on Friday, July 10th. Finally, Royal Bank Of Canada reiterated a “sector perform” rating and issued a GBX 1,350 price objective on shares of Smith & Nephew in a report on Monday, June 29th. Three investment analysts have rated the stock with a Buy rating and six have issued a Hold rating to the stock. According to MarketBeat.com, the stock presently has a consensus rating of “Hold” and a consensus target price of GBX 1,172.56.
Get Our Latest Stock Report on Smith & Nephew
Smith & Nephew Stock Down 6.3%
About Smith & Nephew
Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices and services in the United Kingdom and internationally. It operates through three segments: Orthopaedics, Sports Medicine & ENT, and Advanced Wound Management. The company offers knee implant products for knee replacement procedures; hip implants for revision procedures; trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures; and other reconstruction products.
Recommended Stories
- Five stocks we like better than Smith & Nephew
- SpaceX: Love the Company, But the Stock Is a Harder Call
- Ulta’s Growth Is Real, But So Are the Risks
- BWX Technologies Is Turning the AI Power Problem Into a Nuclear Growth Story
- Meta’s Earnings Drop Shows Wall Street Wants More Than Ad Growth
Receive News & Ratings for Smith & Nephew Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Smith & Nephew and related companies with MarketBeat.com's FREE daily email newsletter.
